Second Sight Medical Products (EYES) Stock Gains on Positive Prosthesis Results

NEW YORK (TheStreet) -- Second Sight Medical Products (EYES) shares are up 5.91% to $16.72 in early market trading on Tuesday after the medical device manufacturer reported positive three year test results from the clinical trials of its Argus II Retinal prosthesis.

The company reported that 89% of subjects showed improved visual functions three years from the start of the trial with Argus II as compared to native residual vision.

The company also reported that none of the trial subjects were affected negatively by the prosthesis while 80% received benefits from the system when considering both functional vision and self-reported quality of life improvements.

EYES Chart EYES data by YCharts

More from Markets

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Oil Prices, China Tariffs, Micron and Kohl's - 5 Things You Must Know

Oil Prices, China Tariffs, Micron and Kohl's - 5 Things You Must Know

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

Global Stocks Push Higher as China Tariff Move, Softer US Dollar Boost Sentiment

Global Stocks Push Higher as China Tariff Move, Softer US Dollar Boost Sentiment